Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003450419 | Skin | AK | protein localization to nucleus | 60/1910 | 290/18723 | 7.27e-08 | 3.53e-06 | 60 |
GO:003238619 | Skin | AK | regulation of intracellular transport | 65/1910 | 337/18723 | 3.23e-07 | 1.27e-05 | 65 |
GO:004682220 | Skin | AK | regulation of nucleocytoplasmic transport | 29/1910 | 106/18723 | 5.12e-07 | 1.85e-05 | 29 |
GO:003315723 | Skin | AK | regulation of intracellular protein transport | 47/1910 | 229/18723 | 2.31e-06 | 6.52e-05 | 47 |
GO:005165618 | Skin | AK | establishment of organelle localization | 69/1910 | 390/18723 | 3.69e-06 | 9.11e-05 | 69 |
GO:000640324 | Skin | AK | RNA localization | 42/1910 | 201/18723 | 4.88e-06 | 1.16e-04 | 42 |
GO:004682523 | Skin | AK | regulation of protein export from nucleus | 12/1910 | 30/18723 | 1.83e-05 | 3.47e-04 | 12 |
GO:000661118 | Skin | AK | protein export from nucleus | 17/1910 | 57/18723 | 3.40e-05 | 5.68e-04 | 17 |
GO:005065718 | Skin | AK | nucleic acid transport | 32/1910 | 163/18723 | 2.14e-04 | 2.39e-03 | 32 |
GO:005065818 | Skin | AK | RNA transport | 32/1910 | 163/18723 | 2.14e-04 | 2.39e-03 | 32 |
GO:005123618 | Skin | AK | establishment of RNA localization | 32/1910 | 166/18723 | 3.02e-04 | 3.12e-03 | 32 |
GO:00510289 | Skin | AK | mRNA transport | 26/1910 | 130/18723 | 5.98e-04 | 5.28e-03 | 26 |
GO:00714266 | Skin | AK | ribonucleoprotein complex export from nucleus | 17/1910 | 76/18723 | 1.43e-03 | 1.05e-02 | 17 |
GO:00711666 | Skin | AK | ribonucleoprotein complex localization | 17/1910 | 77/18723 | 1.66e-03 | 1.18e-02 | 17 |
GO:000941025 | Skin | AK | response to xenobiotic stimulus | 67/1910 | 462/18723 | 1.98e-03 | 1.34e-02 | 67 |
GO:00328865 | Skin | AK | regulation of microtubule-based process | 39/1910 | 240/18723 | 2.32e-03 | 1.53e-02 | 39 |
GO:00315036 | Skin | AK | protein-containing complex localization | 36/1910 | 220/18723 | 2.97e-03 | 1.87e-02 | 36 |
GO:00000548 | Skin | AK | ribosomal subunit export from nucleus | 5/1910 | 14/18723 | 1.00e-02 | 4.80e-02 | 5 |
GO:00337508 | Skin | AK | ribosome localization | 5/1910 | 14/18723 | 1.00e-02 | 4.80e-02 | 5 |
GO:001593118 | Skin | AK | nucleobase-containing compound transport | 34/1910 | 222/18723 | 1.05e-02 | 4.98e-02 | 34 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0516620 | Cervix | CC | Human T-cell leukemia virus 1 infection | 61/1267 | 222/8465 | 8.13e-07 | 7.98e-06 | 4.72e-06 | 61 |
hsa0516414 | Cervix | CC | Influenza A | 43/1267 | 171/8465 | 3.03e-04 | 1.64e-03 | 9.68e-04 | 43 |
hsa05166110 | Cervix | CC | Human T-cell leukemia virus 1 infection | 61/1267 | 222/8465 | 8.13e-07 | 7.98e-06 | 4.72e-06 | 61 |
hsa0516415 | Cervix | CC | Influenza A | 43/1267 | 171/8465 | 3.03e-04 | 1.64e-03 | 9.68e-04 | 43 |
hsa0516626 | Endometrium | AEH | Human T-cell leukemia virus 1 infection | 50/1197 | 222/8465 | 4.30e-04 | 3.11e-03 | 2.27e-03 | 50 |
hsa05166111 | Endometrium | AEH | Human T-cell leukemia virus 1 infection | 50/1197 | 222/8465 | 4.30e-04 | 3.11e-03 | 2.27e-03 | 50 |
hsa0516627 | Endometrium | EEC | Human T-cell leukemia virus 1 infection | 52/1237 | 222/8465 | 2.73e-04 | 2.36e-03 | 1.76e-03 | 52 |
hsa0516636 | Endometrium | EEC | Human T-cell leukemia virus 1 infection | 52/1237 | 222/8465 | 2.73e-04 | 2.36e-03 | 1.76e-03 | 52 |
hsa030137 | Esophagus | HGIN | Nucleocytoplasmic transport | 31/1383 | 108/8465 | 8.29e-04 | 7.95e-03 | 6.31e-03 | 31 |
hsa0516639 | Esophagus | HGIN | Human T-cell leukemia virus 1 infection | 51/1383 | 222/8465 | 5.84e-03 | 4.05e-02 | 3.22e-02 | 51 |
hsa0301312 | Esophagus | HGIN | Nucleocytoplasmic transport | 31/1383 | 108/8465 | 8.29e-04 | 7.95e-03 | 6.31e-03 | 31 |
hsa05166114 | Esophagus | HGIN | Human T-cell leukemia virus 1 infection | 51/1383 | 222/8465 | 5.84e-03 | 4.05e-02 | 3.22e-02 | 51 |
hsa05166211 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
hsa0301321 | Esophagus | ESCC | Nucleocytoplasmic transport | 89/4205 | 108/8465 | 1.20e-12 | 2.37e-11 | 1.21e-11 | 89 |
hsa032509 | Esophagus | ESCC | Viral life cycle - HIV-1 | 54/4205 | 63/8465 | 2.01e-09 | 2.17e-08 | 1.11e-08 | 54 |
hsa0516425 | Esophagus | ESCC | Influenza A | 122/4205 | 171/8465 | 5.01e-09 | 4.79e-08 | 2.45e-08 | 122 |
hsa05166310 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
hsa0301331 | Esophagus | ESCC | Nucleocytoplasmic transport | 89/4205 | 108/8465 | 1.20e-12 | 2.37e-11 | 1.21e-11 | 89 |
hsa0325014 | Esophagus | ESCC | Viral life cycle - HIV-1 | 54/4205 | 63/8465 | 2.01e-09 | 2.17e-08 | 1.11e-08 | 54 |
hsa0516435 | Esophagus | ESCC | Influenza A | 122/4205 | 171/8465 | 5.01e-09 | 4.79e-08 | 2.45e-08 | 122 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
XPO1 | SNV | Missense_Mutation | | c.1508N>G | p.Ser503Cys | p.S503C | O14980 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
XPO1 | SNV | Missense_Mutation | | c.1293N>C | p.Leu431Phe | p.L431F | O14980 | protein_coding | deleterious(0) | possibly_damaging(0.693) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
XPO1 | SNV | Missense_Mutation | rs769916613 | c.40N>T | p.Arg14Cys | p.R14C | O14980 | protein_coding | deleterious(0.03) | benign(0.255) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
XPO1 | SNV | Missense_Mutation | novel | c.2534N>T | p.Arg845Ile | p.R845I | O14980 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
XPO1 | SNV | Missense_Mutation | | c.2246N>A | p.Arg749Gln | p.R749Q | O14980 | protein_coding | deleterious(0) | probably_damaging(0.922) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
XPO1 | SNV | Missense_Mutation | novel | c.1537N>A | p.Glu513Lys | p.E513K | O14980 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
XPO1 | SNV | Missense_Mutation | | c.1943N>T | p.Thr648Ile | p.T648I | O14980 | protein_coding | tolerated(0.22) | benign(0) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
XPO1 | SNV | Missense_Mutation | | c.3033N>G | p.Phe1011Leu | p.F1011L | O14980 | protein_coding | deleterious(0.02) | benign(0.033) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
XPO1 | SNV | Missense_Mutation | | c.1711N>A | p.Glu571Lys | p.E571K | O14980 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A18F-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
XPO1 | SNV | Missense_Mutation | | c.1711N>A | p.Glu571Lys | p.E571K | O14980 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A203-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7514 | XPO1 | CLINICALLY ACTIONABLE, KINASE | inhibitor | CHEMBL3545185 | SELINEXOR | |
7514 | XPO1 | CLINICALLY ACTIONABLE, KINASE | | Selinexor oral | | |
7514 | XPO1 | CLINICALLY ACTIONABLE, KINASE | | SL-801 | CBS-9106 | |
7514 | XPO1 | CLINICALLY ACTIONABLE, KINASE | | KOS-1815 | | 24631834 |
7514 | XPO1 | CLINICALLY ACTIONABLE, KINASE | | Eltanexor oral | | |
7514 | XPO1 | CLINICALLY ACTIONABLE, KINASE | | LEPTOMYCIN B | LEPTOMYCIN B | 18835718 |
7514 | XPO1 | CLINICALLY ACTIONABLE, KINASE | inhibitor | 375973225 | ELTANEXOR | |
7514 | XPO1 | CLINICALLY ACTIONABLE, KINASE | | KPT-330 | SELINEXOR | 24631834 |
7514 | XPO1 | CLINICALLY ACTIONABLE, KINASE | | isoniazid | ISONIAZID | 22341855,29036176 |
7514 | XPO1 | CLINICALLY ACTIONABLE, KINASE | | GONIOTHALAMIN | GONIOTHALAMIN | 20381347 |